Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26962612 | 1.00 | HDAC6 (0.38) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL31628392 | 0.91 | HDAC6 (0.40) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL31375533 | 0.91 | HDAC6 (0.40) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL30830371 | 0.88 | HDAC6 (0.40) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL31628095 | 0.87 | GAA (0.36) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL26962169 | 0.87 | HDAC6 (0.39) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL31375592 | 0.86 | BDKRB1 (0.35) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL31628240 | 0.86 | BDKRB1 (0.35) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL31375493 | 0.86 | GAA (0.34) | GAA | |
| SCHEMBL31375596 | 0.82 | GAA (0.37) | HDAC6HDAC1HDAC8HDAC4HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | HDAC6 659/4885HDAC1 14/4885HDAC8 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.